Variability in golimumab exposure: A 'real-life' observational study in active ulcerative colitis

Journal of Crohn's and Colitis

Volumn 10, Issue 5, 2016, Pages 575-581

  Detrez, Iris ^a   Dreesen, Erwin ^a   Van Stappen, Thomas ^a   de Vries, Annick ^b   Brouwers, Els ^a   Van Assche, Gert ^c   Vermeire, Séverine ^c   Ferrante, Marc ^c   Gils, Ann ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b Sanquin Diagnostiek   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Golimumab; Therapeutic drug monitoring; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; C REACTIVE PROTEIN; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GOM131E3; MONOCLONAL ANTIBODY GOM159B8; MONOCLONAL ANTIBODY GOM171D8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DELAYED HYPERSENSITIVITY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG BLOOD LEVEL; DRUG CHRONOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFUSION RELATED REACTION; MAINTENANCE DRUG DOSE; MALE; MAYO SCORE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS; BLOOD; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; DRUG MONITORING; DRUG TOLERANCE; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG TOLERANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84982218441     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv241     Document Type: Article

References (17)

1. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med 2011;365: 1713-25.
2. Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis-past, present and future. Aliment Pharmacol Ther 2013;37:855-66.
3. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2: 219-25.
4. Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: A 'real-life' observational study. Dig Liver Dis 2013;45:738-43.
5. Hutas G. Golimumab, a fully human monoclonal antibody against TNFa. Curr Opin Mol Ther 2008;10:393-406.
6. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010;2:428-39.
7. Löwenberg M, De Boer NKH, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:53-9.
8. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2014;146:85-95.
9. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2014;146:96-109.
10. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of Early Response to Infliximab in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2007;13:123-8.
11. Van Stappen T, Brouwers E, Tops S, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit 2015;37:479-85.
12. Gils A, Vande Casteele N, Poppe R, et al. Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization. Ther Drug Monit 2014;36:669-73.
13. van Schie KA, Hart MH, de Groot ER, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:311-4.
14. Van Stappen T, Billiet T, Vande Casteele N, et al. An optimized anti-infliximab bridging ELISA for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:2172-7.
15. Cohena LB, Nanauc RM, Delzord F, et al. Biologic therapies in inflammatory bowel disease. Transl Res 2014;163:533-56.
16. Van Schouwenburg PA, Krieckaert CL, Rispens, T et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
17. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71.